Bain Capital Life Sciences Investors’s Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third PANA.U Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio PANA.U Stock Details PANA.U Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-500,000	Closed	-$5M	–	29
2020 Q3	$5M	Buy	+500,000	New	+$5.75M	0.47%	22

Other funds holding PANA.U

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Bain Capital Life Sciences Investors's PANA.U Position: Q4 2020 in Review

Bain Capital Life Sciences Investors sold out of Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third (PANA.U) in Q4 2020, closing a stake of 500,000 shares — an estimated $5M sold.

Bain Capital Life Sciences Investors first reported a position in PANA.U in Q3 2020 and held it in 1 quarter. The position peaked at $5M in Q3 2020. 22 funds tracked by Wall St. Rank hold PANA.U as of Q4 2020.

Bain Capital Life Sciences Investors reported no remaining Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third position as of Q4 2020 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 500,000 Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third shares in Q4 2020, an estimated $5M.
Bain Capital Life Sciences Investors first reported a position in Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third in Q3 2020 and held it in 1 quarter.
Bain Capital Life Sciences Investors's Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third position peaked at $5M in Q3 2020.
22 funds tracked by Wall St. Rank held Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third as of Q4 2020.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2020, filed 16 Feb 2021.